Evidence map›Paper›PMID 30127946›Full record

ArticleOncology letters2018

Gang Hu, Yixin Zhang, Kedong Ouyang, Fubo Xie, Houshun Fang, Xueyang Yang, Kunyan Liu, Zongyu Wang, Xuzhen Tang, Jibin Liu and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Hepatocellular carcinoma drug resistance models.Cancer cell international · 2025
    Review
  4. Review
  5. Review
  6. Tumour evolution in hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2020
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Gang HuJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China.
Yixin ZhangDepartment of Surgery, Nantong Cancer Hospital, Nantong, Jiangsu 226361, P.R. China.
Kedong OuyangShanghai ChemPartner Co., Ltd., Shanghai 201203, P.R. China.
Fubo XieShanghai ChemPartner Co., Ltd., Shanghai 201203, P.R. China.
Houshun FangShanghai ChemPartner Co., Ltd., Shanghai 201203, P.R. China.
Xueyang YangShanghai ChemPartner Co., Ltd., Shanghai 201203, P.R. China.
Kunyan LiuShanghai ChemPartner Co., Ltd., Shanghai 201203, P.R. China.
Zongyu WangShanghai ChemPartner Co., Ltd., Shanghai 201203, P.R. China.
Xuzhen TangShanghai ChemPartner Co., Ltd., Shanghai 201203, P.R. China.
Jibin LiuDepartment of Surgery, Nantong Cancer Hospital, Nantong, Jiangsu 226361, P.R. China.
Lei YangDepartment of Surgery, Nantong Cancer Hospital, Nantong, Jiangsu 226361, P.R. China.
Zhenzhou JiangJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China.
Weikang TaoShanghai ChemPartner Co., Ltd., Shanghai 201203, P.R. China.
He ZhouShanghai ChemPartner Co., Ltd., Shanghai 201203, P.R. China.
Luyong ZhangJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China.
China Pharmaceutical University · CNNantong Tumor Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acquired resistance to targeted therapies is an important clinical challenge. Research focusing on acquired resistance is hindered by the lack of relevant model systems. In the present study, the generation and characterization of an

Indexed as

acquired resistancefibroblast growth factorhepatocellular carcinomapatient-derived xenograftsorafenib

Identifiers

PMID30127946
PMCPMC6096179
OpenAlexW2809956364

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.